Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
Authors
Keywords
Ovarian cancer, Recurrent ovarian cancer, Platinum sensitive, Platinum resistant, Platinum refractory, Symptom burden, Symptom benefit, Magnitude of clinical benefit, Net health benefit, Patient-reported outcome, PRO, Patient-reported outcome measure, PROM, Quality of life, QOL, Health-related quality of life, HRQOL, HRQL
Journal
QUALITY OF LIFE RESEARCH
Volume 27, Issue 1, Pages 59-74
Publisher
Springer Nature
Online
2017-12-16
DOI
10.1007/s11136-017-1729-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease
- (2016) M. K. Wilson et al. ANNALS OF ONCOLOGY
- Patient-reported outcomes (PRO) in ovarian cancer clinical trials—lost opportunities and lessons learned: Table 1.
- (2016) M. Friedlander et al. ANNALS OF ONCOLOGY
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
- (2015) N. I. Cherny et al. ANNALS OF ONCOLOGY
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- (2015) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- Reflective, causal, and composite indicators of quality of life: A conceptual or an empirical distinction?
- (2015) Daniel S. J. Costa QUALITY OF LIFE RESEARCH
- “Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
- (2014) Alison Davis et al. GYNECOLOGIC ONCOLOGY
- Symptom Burden and Outcomes of Patients With Platinum Resistant/Refractory Recurrent Ovarian Cancer
- (2014) Michael Leonard Friedlander et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Development of the Measure of Ovarian Symptoms and Treatment Concerns
- (2014) Madeleine T. King et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
- (2012) L. C. Hanker et al. ANNALS OF ONCOLOGY
- Clinical Trials in Recurrent Ovarian Cancer
- (2011) Michael Friedlander et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer
- (2011) Gavin C.E. Stuart et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- A new index of priority symptoms in advanced ovarian cancer
- (2010) Sally E. Jensen et al. GYNECOLOGIC ONCOLOGY
- Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
- (2010) Jalid Sehouli et al. JOURNAL OF CLINICAL ONCOLOGY
- Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
- (2010) Kim Cocks et al. JOURNAL OF CLINICAL ONCOLOGY
- Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes
- (2009) Ethan Basch et al. JNCI-Journal of the National Cancer Institute
- Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes
- (2007) Dennis Revicki et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started